Published in JAMA · View the paper (DOI)
A large-scale database study has provided solid evidence for using semaglutide and tirzepatide to treat heart failure with preserved ejection fraction. The medications have been shown to reduce the risk of hospitalization for heart failure or death by more than 40 percent in patients with this form of the disease.
Coverage from 2 institutions